Abstract

Human Microphysiological Systems (hMPS), otherwise known as organ- and tissue-on-a-chip models, are an emerging technology with the potential to replace in vivo animal studies with in vitro models that emulate human physiology at basic levels. hMPS platforms are designed to overcome limitations of two-dimensional (2D) cell culture systems by mimicking 3D tissue organization and microenvironmental cues that are physiologically and clinically relevant. Unlike animal studies, hMPS models can be configured for high content or high throughput screening in preclinical drug development. Applications in modeling acute and chronic injuries in the musculoskeletal system are slowly developing. However, the complexity and load bearing nature of musculoskeletal tissues and joints present unique challenges related to our limited understanding of disease mechanisms and the lack of consensus biomarkers to guide biological therapy development. With emphasis on examples of modeling musculoskeletal tissues, joints on chips, and organoids, this review highlights current trends of microphysiological systems technology. The review surveys state-of-the-art design and fabrication considerations inspired by lessons from bioreactors and biological variables emphasizing the role of induced pluripotent stem cells and genetic engineering in creating isogenic, patient-specific multicellular hMPS. The major challenges in modeling musculoskeletal tissues using hMPS chips are identified, including incorporating biological barriers, simulating joint compartments and heterogenous tissue interfaces, simulating immune interactions and inflammatory factors, simulating effects of in vivo loading, recording nociceptors responses as surrogates for pain outcomes, modeling the dynamic injury and healing responses by monitoring secreted proteins in real time, and creating arrayed formats for robotic high throughput screens. Overcoming these barriers will revolutionize musculoskeletal research by enabling physiologically relevant, predictive models of human tissues and joint diseases to accelerate and de-risk therapeutic discovery and translation to the clinic.

Highlights

  • Musculoskeletal conditions encompass a wide spectrum of pain or damage associated with muscle, bone, cartilage, tendon, ligament, joints, and nerves

  • 4.1.4 Induced Pluripotent Stem Cells The Noble prize discovery that somatic cells can be reprogrammed to turn back the clock and induce a pluripotent stem cell-like state opens limitless possibilities for applications in microphysiological systems (MPS) models. induced pluripotent stem cells (iPSCs) were originally derived from murine embryonic and adult fibroblasts through viral transfection with Oct3/4, Klf4, Sox2, and c-Myc pluripotency factors (Takahashi and Yamanaka, 2006)

  • Semipermeable membranes separate chambers into two compartments allowing molecular and cellular transport only through nano- to micro-sized pores, respectively. These can be of particular importance in musculoskeletal tissues as fluid flow is incorporated to simulate vasculature, synovial fluid, or interstitial flow and cell cultures are required to be in suspension or direct contact with other cells or tissues

Read more

Summary

INTRODUCTION

Musculoskeletal conditions encompass a wide spectrum of pain or damage associated with muscle, bone, cartilage, tendon, ligament, joints, and nerves. MPS are a disruptive technology platform for evaluating safety and efficacy during the early stages of drug and therapeutic development and informing the planning and execution of clinical trials This was recently demonstrated by a breakthrough study that used MPS of vascularized human kidney spheroids with integrated tissue-embedded microsensors for oxygen, glucose, lactate, and glutamine to provide real-time assessment of nephrotoxicity of immunosuppressive (cyclosporine) and anticancer (cisplatin) drugs. The sensor-enabled kidney-on-a-chip prediction of safety and efficacy of the combination therapy was validated through retrospective analysis of a clinical study involving 247 patients receiving cyclosporine or cisplatin alone or in combination with the SGLT2 inhibitor empagliflozin (Cohen et al, 2021) Such works are paving the way for MPS technology to transform drug development and patient healthcare. In addition to providing an overview of critical issues in MPS, the review discusses specific challenges that should be prioritized in future MPS models of musculoskeletal diseases to accelerate their adoption into the drug and therapeutic discovery pipeline and in virtual clinical trials

FROM BIOREACTORS TO MICROPHYSIOLOGICAL SYSTEMS
FROM ORGANOIDS TO ORGAN-ON-A-CHIP
Cell Sources
Primary Cells
Immortalized Cell Lines
Stem Cells
Induced Pluripotent Stem Cells The
Extracellular Matrix Biomaterials
Fabrication Materials in MPS Devices
Elastomers Elastomers are cross-linked polymers with weakly entangled chains
Rigid Polymers
CHALLENGES FOR MUSCULOSKELETAL MPS
Semipermeable Membranes
Hydrogel-Liquid Interface
Microchannels
Vascular Networks Embedded in ECM
Engineered Heterogenous Tissue Interfaces
Incorporation of Immune Cells and Inflammatory Factors
Biomechanical Actuation and Loading
Afferent Nociceptive Signaling (Pain) Outcomes
Integration of Sensors
Arrayed Formats for High Throughput Screening
Findings
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call